---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-009009"
form_type: "8-K"
ticker: "ACRS"
cik: "0001557746"
company_name: "Aclaris Therapeutics, Inc."
filed_at: "2024-06-07T23:59:59+00:00"
generated_at: "2026-06-01T05:33:54.446485+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Aclaris shareholders elect two directors, approve say-on-pay, ratify auditor at 2024 annual meeting

## Summary
- Elected Christopher Molineaux (29.2M for, 16.2M withheld) and Vincent Milano (42.3M for, 3.1M withheld) as directors.
- Advisory vote on executive compensation approved: 29.0M for, 16.3M against, 21k abstain, with 12.5M broker non-votes.
- Ratified PricewaterhouseCoopers as auditor for FY2024: 56.6M for, 1.2M against, 23k abstain.
- Turnout of 81.09% (57.8M of 71.3M shares outstanding) present or represented at meeting.

## SEC filing metadata
- accession: 0001558370-24-009009
- form_type: 8-K
- ticker: ACRS
- cik: 0001557746
- company_name: Aclaris Therapeutics, Inc.
- filed_at: 2024-06-07T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557746/000155837024009009/0001558370-24-009009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557746/000155837024009009/acrs-20240606x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-009009
- JSON: https://secwatch.observer/filing/0001558370-24-009009.json
- Plain text: https://secwatch.observer/filing/0001558370-24-009009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.